Exclusive-Kimberly-Clark readies asset sales in bid for EU nod for Kenvue deal, sources say
Kimberly-Clark is preparing asset sales to secure EU approval for its proposed Kenvue deal, according to sources cited by Investing.com. The concessions could reduce regulatory friction but add execution risk and raise questions about the transaction’s eventual scope.
Investing.com reported that Kimberly-Clark is readying asset sales as it seeks approval from European Union regulators for its proposed acquisition of Kenvue, citing people familiar with the matter. The report did not identify the assets under consideration, their value, or whether the European Commission has formally requested specific remedies.
The move comes as Kimberly-Clark works to clear the deal with competition authorities rather than treating the transaction as a solely commercial combination. The report did not say whether the EU has accepted the proposed concessions, set a deadline for a decision, or indicated that asset sales would be sufficient to resolve its concerns.
For Kimberly-Clark, the mechanism is direct: divestitures could make the transaction more acceptable to regulators, but they could also remove brands, products or operations from the combined business and add separation costs. Kenvue is the consumer-health company involved in the deal; its reported FY2025 revenue was $15.1B, while Kimberly-Clark reported FY2025 revenue of $16.4B.
The central uncertainty is the source reporting itself: the claims were attributed to unnamed sources, and Investing.com did not disclose the assets, the expected proceeds or the EU’s specific objections. No formal regulatory decision or company announcement was cited.
The next decisive markers are Kimberly-Clark’s disclosure of any remedy package, a formal European Commission decision, and the companies’ next results updates. The open questions are whether the sales would materially change the deal economics and whether regulators in other jurisdictions require additional concessions.
The reported asset sales keep the Kenvue transaction viable for KMB but shift the risk toward a smaller or less valuable deal.
The setup is balanced: concessions could preserve Kimberly-Clark’s access to Kenvue, but undisclosed divestitures may dilute the strategic and financial benefits before approval is secured. The reported FY2025 revenue bases—$16.4B for KMB and $15.1B for KVUE—underline the scale of the combination, while the absence of remedy details prevents a stronger directional read.
The trade is invalidated by a formal EU remedy package that materially shrinks the transaction or by regulators rejecting the deal.
CoverageSource: Investing.com · Published here MON, SEP 14 · 10:25 AM ET · the only report in this recordHow this is decided →
STOCK PHOTO · PIXABAYEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Asset sales could address the EU’s concerns and keep the proposed Kenvue combination on track.
The reported need for divestitures signals that approval may require concessions that reduce the deal’s value; the assets and terms remain undisclosed.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →